Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 486 participants.
Also called NCT01623115
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 486 participants
- Sponsor
- Registry
-
NCT01623115 -
2011-005109-56
-
- Other papers using this trial's data
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Canada, Czechia, Denmark, France, Israel, Netherlands, Norway, Russia, South Africa, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01623115. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
- Acronym
- ODYSSEY FH I
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Lipid Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01623115- Content hash
487ae1ff9be0a3710b656429c351f91af57fd73be6f4cd290591c60048622575